title: Augmentation of protein degradation by L-triiodothyronine in uremia.
abstract: To ascertain if excessive protein catabolism is a feature of uremia, we determined leucine flux and nitrogen balance in 11 stable chronic dialysis patients and in 7 normal subjects. Leucine flux was determined during primed constant infusion of 2H3 and 15N leucine. Nitrogen balance was determined by measurement of nitrogen in the food, dialysate, and urine, and in the dialysis patients by correcting for the changing urea nitrogen pool. To assess if thyroid hormone adversely affects protein metabolism, the above-mentioned studies were done once in the basal state and once after a 7-day course of L-triiodothyronine (T3) treatment. Leucine carbon flux (mumol/kg/min) was 1.22 +/- 0.05 in the controls and 1.40 +/- 0.09 in the renal patients in the basal state (P = NS). Following T3 treatment, leucine carbon flux was increased to 1.40 +/- 0.05 and 1.72 +/- 0.09, respectively, in the controls and the renal patients (P less than .05). Fractional increment of the leucine carbon flux was 14% +/- 3% in the controls and 23% +/- 9% in the renal patients (P less than .05). The leucine nitrogen flux (mumol/kg/min) was 2.10 +/- 0.15 in the controls and 2.54 +/- 0.23 in the renal patients in the basal state (P = NS), and increased to 2.48 +/- 0.14 and 3.44 +/- 0.22, respectively, in controls and renal patients after T3 administration (P less than .05). Fractional increment of leucine nitrogen flux was 19.5% +/- 4.3% in the controls and 36.4% +/- 5.0% in the renal patients (P less than .05).(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Veteran Administration Medical Center, Iowa City, IA.
authors.forename: V S
authors.initials: VS
authors.lastname: Lim
authors.forename: E
authors.initials: E
authors.lastname: Tsalikian
authors.forename: M J
authors.initials: MJ
authors.lastname: Flanigan
mesh_terms: D000328:Adult; D002845:Chromatography / Q000379:methods; D002149:Energy Intake; D004734:Energy Metabolism; D005260:Female; D005504:Food Analysis; D006801:Humans; D007930:Leucine / Q000008:administration & dosage* / Q000493:pharmacokinetics; D008297:Male; D008875:Middle Aged; D009584:Nitrogen / Q000378:metabolism; D010949:Plasma / Q000032:analysis; D011506:Proteins / Q000032:analysis / Q000378:metabolism*; D011863:Radioimmunoassay; D006435:Renal Dialysis; D013960:Thyroid Function Tests; D014284:Triiodothyronine / Q000008:administration & dosage* / Q000627:therapeutic use; D014508:Urea / Q000378:metabolism; D014511:Uremia / Q000378:metabolism* / Q000628:therapy
chemical_list: D011506:Proteins; D014284:Triiodothyronine; D014508:Urea; D007930:Leucine; D009584:Nitrogen